Standard BioTools

Standard BioTools Gross Profit

The Gross Profit of Standard BioTools (LAB) as of Nov 5, 2026 is 42.54 M USD. In the previous year, Gross Profit was 84.26 M USD — a change of -49.51% (lower).

Gross Profit

42.54 MUSD

YoY

-49.51%

Last updated:

Gross Profit of Standard BioTools is 2025 42.54 M USD. Gross Profit of Standard BioTools was 2024 84.26 M USD. It decreases by -49.51% lower compared to the previous year.

The Standard BioTools Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
61.65 M USD
Jan 1, 2019
64.28 M USD
Jan 1, 2020
83.33 M USD
Jan 1, 2021
77.27 M USD
Jan 1, 2022
37.05 M USD
Jan 1, 2023
50.45 M USD
Jan 1, 2024
84.26 M USD
Jan 1, 2025
42.54 M USD
The Standard BioTools Gross Profit history
YEARGross ProfitYoY
42.54 MUSD-49.51%
84.26 MUSD+67.02%
50.45 MUSD+36.16%
37.05 MUSD-52.05%
77.27 MUSD-7.27%
83.33 MUSD+29.63%
64.28 MUSD+4.27%
61.65 MUSD+18.60%
51.98 MUSD-11.05%
58.44 MUSD-14.17%
68.08 MUSD-7.51%
73.61 MUSD+44.04%
51.10 MUSD+38.08%
37.01 MUSD+24.72%
29.67 MUSD+35.01%
21.98 MUSD+57.83%
13.93 MUSD+99.43%
6.98 MUSD+85.67%
3.76 MUSD+3.75%
3.63 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Revenue

Standard BioTools Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
97.95 M USD
-188.60 M USD
-190.10 M USD
Jan 1, 2023
106.34 M USD
-76.60 M USD
-74.66 M USD
Jan 1, 2024
174.43 M USD
-175.24 M USD
-138.89 M USD
Jan 1, 2025
85.33 M USD
-93.31 M USD
-74.90 M USD
Jan 1, 2026 (e)
82.50 M USD
-35.53 M USD
-38.46 M USD
Jan 1, 2027 (e)
82.10 M USD
-58.42 M USD
-61.53 M USD
Jan 1, 2028 (e)
85.70 M USD
-50.79 M USD
-53.84 M USD
Jan 1, 2029 (e)
89.40 M USD
-54.61 M USD
-57.69 M USD

Standard BioTools Margins

Standard BioTools stock margins

The Standard BioTools margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Standard BioTools. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Standard BioTools.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
37.83 %
-192.55 %
-194.08 %
Jan 1, 2023
47.44 %
-72.03 %
-70.21 %
Jan 1, 2024
48.31 %
-100.46 %
-79.62 %
Jan 1, 2025
49.86 %
-109.34 %
-87.77 %
Jan 1, 2026 (e)
49.86 %
-43.06 %
-46.61 %
Jan 1, 2027 (e)
49.86 %
-71.16 %
-74.95 %
Jan 1, 2028 (e)
49.86 %
-59.27 %
-62.82 %
Jan 1, 2029 (e)
49.86 %
-61.08 %
-64.53 %

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Gross Profit of Standard BioTools is 42.54 M USD in 2025.

Gross Profit of Standard BioTools changed from 84.26 M USD to 42.54 M USD, representing a -49.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Standard BioTools

All Key Metrics — Standard BioTools